Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Heidelberg University Researchers Classify Brain and Spine Metastases

Published: Monday, February 07, 2011
Last Updated: Monday, February 07, 2011
Bookmark and Share
Researchers at the Department of Neuropathology at Heidelberg University in Germany have shown that Rosetta Genomics' miRview™ mets is a powerful tool to guide diagnosis of metastatic brain and spine cancer cases. The study, titled "Accurate Classification of Metastatic Brain Tumors Using a Novel MicroRNA-Based Test," was published online, January 31, and is set to be published in the February 11, 2011 print edition of The Oncologist.

The abstract of the study may be viewed online at The Oncologist website: http://theoncologist.alphamedpress.org/cgi/content/abstract/theoncologist.2010-0305v1

The study consisted of a proof-of-concept phase and a validation phase. In the proof-of-concept phase, brain and spine metastases from known primary tumors were analyzed with the miRview™ mets assay. In the validation phase, a cohort of brain and spine metastatic samples of true Cancer of Unknown Primary patients were studied, and concordance between results generated by miRview™ mets and the clinical and pathological evaluation was examined.
Results from the validation phase demonstrated that primary origin prediction from miRview™ mets was in agreement with the clinical or pathological evaluation in 80% of the cases.
Underscoring the value of miRview™ mets, the study describes a case of a breast cancer patient with brain metastasis. When analyzed with miRview™ mets, the origin of the metastasis was surprisingly diagnosed as melanoma. Additional pathology testing supported this diagnosis. Based on these findings, the primary breast cancer was also tested with the miRview™ mets assay as well as additional pathology testing, and was found to be melanoma misdiagnosed as breast cancer.

"Metastatic cancer can present a significant diagnostic challenge to pathologists searching for the primary origin," noted Dr. Wolf C. Mueller from the Department of Neuropathology at Heidelberg University, who led the study. "The diagnostic process can be time-consuming, and can lead to limited results. Our study demonstrated that miRview™ mets is a powerful tool for diagnosing cancer of uncertain or unknown primary, and may also offer new diagnostic avenues to explore."

"This study, along with the recently completed study by researchers from M. D. Anderson, are two post-marketing validation studies conducted by leading cancer centers that demonstrate the ability of miRview™ mets to accurately identify the origin of metastases in cancer cases with unknown or uncertain primaries. We are pleased with the consistently strong performance of our microRNA-based assay in diagnosing cancer of true uncertain or unknown primary," noted Kenneth A. Berlin, President and CEO of Rosetta Genomics. "Our unique microRNA-based technologies have enabled us to recently launch miRview™ mets², and we firmly believe that with its expanded tumor panel and enhanced classifiers, it will further improve physicians' ability to accurately diagnose cancer of unknown or uncertain primary origin in order to optimize treatment options for patients."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Allogeneic Stem Cell Transplant Shows Promise for Treatment-Resistant CLL
University of Heidelberg researchers publish study results in the journal Blood.
Wednesday, July 07, 2010
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!